← Oncology Approval Tracker

FDA DECISION ·

Elahere

mirvetuximab soravtansine-gynx · ImmunoGen (AbbVie)

Traditional approvalTraditional conversionOvarian, fallopian tube and primary peritoneal cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with FDA test-confirmed FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three systemic regimens.

LAMPGEN ANALYSIS

Why it matters

The randomized MIRASOL results confirmed benefit and supported conversion of the 2022 accelerated indication.

What research teams should watch

Confirm FRα testing and regimen count, and align ophthalmic care and dose modification with the treatment cycle.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Platinum-resistant recurrent disease

PRIMARY RECORDS

Sources